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neuronal GABA concentrations by both 
inhibiting its metabolism and increasing its 
synthesis [1].
Preclinical research on animal models 
has shown the involvement of ion channels, 
monoamines, the corticotropin-releasing 
INTRODUCTION
Valproic acid (VPA), a branched short-
chain fatty acid, is a widely used anti-epi-
leptic drug with a broad spectrum of activity 
and mechanisms of action [1]. It is used for 
the treatment of several types of seizure and 
epileptic syndromes, including generalized 
and focal seizures [2]. Moreover, it is com-
monly used for migraine prophylaxis and in 
the treatment of bipolar disorder, as a mood 
tone stabilizer. VPA, as a therapeutic agent, 
is commercially available as Depakote®, De-
pakote ER®, Depakene®, Depacon®, Stavzor®, 
Mylproin®, Ergenyl®, Dipropylacetic acid, 
Myproic Acid, and Convulex®.
To date, its mechanism of action has 
not yet been fully clarified. Although VPA 
does not directly interact with postsynaptic 
GABA receptors, it does increase regional 
Why Do we Describe This Case
To the best of our knowledge, very few 
cases of adult hypoglycemia induced 
by therapeutical VPA levels have been 
reported to date. Moreover, this case 
evidences that the suspicion of an iatro-
genic pathogenesis should be explored in 
patients on chronic antiepileptic therapy 




Literature on antiepileptic-induced iatrogenic hypoglycemia is scanty. Due to its broad spectrum 
of activity and mechanisms of action, valproic acid (VPA), a fatty acid, is one of the most widely 
prescribed epilepsy treatments worldwide.
Herein, we describe an adult epileptic patient, in whom persistent, otherwise unexplained, 
hypoglycemia was most likely induced by VPA, as suggested by the VPA and glucose blood level 
time course. Indeed, no further hypoglycemic episodes occurred after VPA discontinuation and 
the diagnostic work-up ruled out other possible causes of hypoglycemia.
This case supports the hypothesis that VPA may induce hypoglycemia, even in the absence of a 
VPA hepatotoxicity syndrome, due to still not well-defined metabolic mechanisms of action. 
Moreover, it emphasizes the fact that an iatrogenic pathogenesis should be considered if an 
apparently unexplained hypoglycemia occurs in a patient on chronic therapy with VPA, even 
at a therapeutical dosage.
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He had been on VPA therapy, at 1000 mg 
bid, for about a year before being hospital-
ized in our department. Two EEGs per-
formed in the previous 2 months had shown 
no evidence of epilepsy.
The patient had been admitted to our 
Emergency Department the previous 
month for respiratory failure and bilateral 
pneumonia, which had evolved into septic 
shock requiring Intensive Care. Although 
recurrent hypoglycemia was observed, it 
was attributed both to the septic state and 
his reduced food intake.
His hepatic function was normal, i.e., 
alanine transaminase 30 mg/dl, aspartate 
transaminase 35 mg/dl, and ammonium 
levels were within normal levels (35 mg/dl), 
as was the renal function.
When he arrived in our Division, he was 
still on maintenance therapy, i.e., methyl-
prednisolone (40 mg daily), prescribed when 
he had been admitted to the ICU, and ris-
peridone 1 mg daily: no variation was made 
to the treatment. He had continuous glucose 
infusions.
The patient was transferred to an Internal 
Medicine Department after a week, where 
the hypoglycemia episodes persisted and a 
generalized epileptic seizure occurred, even 
though his VPA plasma levels were in the 
therapeutic range.
A more in-depth medical history brought 
to light two previous diabetology consulta-
tions for hypoglycemia in the previous year. 
As the first hypothesis was that his symp-
toms were attributable to metformin, it was 
discontinued. Clinical investigations were 
made, firstly a diabetology assessment, dos-
ing of C-peptide (it was within normal lim-
its), and an abdomen CT scan.
The simultaneous determination of in-
sulinemia and blood glucose, the insulin-
blood glucose ratio and the concomitant 
determination of insulinemia and blood 
glucose during 24-48-72 hours of fasting 
were unremarkable.
No neuroendocrine tumor was found by 
the abdomen CT scan, and neuron-specific 
enolase and chromogranin A were normal.
An iatrogenic effect was then hypoth-
esized, with the suspicion that VPA played 
some kind of role. Therefore, the patient was 
transferred back to the Neurology Unit for 
rapid VPA withdrawal (500 mg bid for two 
days, then withdrawn), switching to leveti-
racetam (LVT) at 1000 mg bid.
The hypoglycemic episodes persisted for 
another week, especially during the morning.
factor, and intracellular signaling proteins 
in the mechanism of action of VPA [2,3]. It 
has also recently emerged that VPA inhib-
its histone deacetylation and regulates the 
transcription of various genes. This effect 
implies it has a potential role as anti-cancer 
drug and as possible antidiabetic agent [4].
However, it has been demonstrated that 
VPA administration may cause numerous 
side effects and/or pharmacological inter-
ference and, thus, requires strict clinical 
and laboratory control, with serum level 
monitoring [5]. Indeed, VPA can lead to 
hyponatremia due to an inappropriate an-
tidiuretic hormone secretion. It can also 
cause hematologic toxicity (thrombocytope-
nia, leucopenia, macrocytic anemia), severe 
liver damage, kidney failure, hypothyroid-
ism, hyperammonemia, rhabdomyolysis, 
hyperandrogenism, pancreatitis, as well as 
teratogenicity. The mechanisms underlying 
most of these side effects have not yet been 
completely understood [3,6,7].
It has been reported that drug-induced 
hypoglycemia as a cause of acute medical 
admissions ranges from 0.1% to 1.7% [8]. 
Literature reports several types of non-dia-
betic drugs that may induce hypoglycemia, 
including: NSAIDs, analgesics, antibac-
terials, antimalarials, pentamidine, ß-ad-
renergic receptor antagonists (ß-blockers), 
antiarrhythmics, ACE-inhibitors, fibrates, 
and antidepressants [9]. Ben Salem et al. 
also reported that some antiepileptic drugs 
(gabapentin, phentoin, topiramate) caused 
iatrogenic hypoglycemia [9]. It was hypoth-
esized that the underlying mechanisms were 
insulin release or the reduction of its clear-
ance, and/or an interference in the glucose 
metabolism [9].
Herein, we report a case of persistent 
hypoglycemia episodes, which were most 
likely induced by VPA, administered at an 
appropriate dosage in an epileptic patient.
CASE PRESENTATION
A 49-year-old male, affected by an epilep-
tic syndrome from the birth, was admitted 
to our Neurology Unit for recurrent focal 
seizures to bilateral tonic-clonic seizures. 
His clinical history included diabetes mel-
litus (DM) type 2 treated by metformin, 
oligophrenia, associated with the epileptic 
syndrome, which was probably structural, 
related to perinatal hypoxic damage, and sec-
ondary psychosis, treated with risperidone.
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tal metabolic diseases, and extra-pancreatic 
cancers), as well as functional endogenous 
causes (postprandial reactive hypoglycemia, 
pituitary and cortico-surrenalic insufficiency, 
liver disease, malnutrition), and a VPA hepa-
totoxicity syndrome.
As the C-peptide connects the insulin 
A-chain  to its  B-chain  in the  proinsulin 
molecule, it was dosed. Proinsulin is the 
precursor of the insulin synthesized in the 
ß-pancreatic cells. As C-peptide and insulin 
are released into the circulation in equimo-
lar quantities by pancreas ß-cells, assessing 
circulating C-peptide levels provides an 
indirect evaluation of insular ß activity. C-
peptide assessment is often preferred to in-
sulin assessment as it is metabolized in the 
proximal renal tubes and not by the liver and 
has a slower metabolism and lacks cross-
reactivity with antibodies directed towards 
insulin [10]. In our patient, the C-peptide 
tuned out to within the normal limits.
Moreover, the VPA level decrease ob-
served after withdrawal was followed by a 
blood glucose increase (Figure 1), supporting 
the hypothesis that VPA played a direct role 
in hypoglycemia as a side effect, even though 
the decline in VPA serum concentrations 
took somewhat longer than expected.
This time course of VPA level decrease 
and glucose rise, after a week interval from 
the VPA nadir, pointed to a possible role of 
other factors, mainly pharmacological (the 
other drugs co-administered), but also clini-
cal (the comorbidities), which might have af-
It took 7 days for the blood glucose val-
ues to normalize after VPA withdrawal 
(Figure 1). A steady normoglycemic state 
was then maintained and epilepsy was kept 
under good control by levetiracetam.
DISCUSSION
VPA is known to have several side effects, 
including teratogenicity and hyperammone-
mia, with possible serious encephalopathy 
[3,6] and it is difficult to predict the indi-
vidual response to treatment and the appear-
ance of side effects.
The recent developments of pharmacoge-
nomics has brought to light the fact that 
there are numerous genes which may influ-
ence VPA metabolism, efficacy and safety. 
This may, in part, explain the individual 
variability of plasma levels and the onset 
of some serious side effects, including liver 
toxicity and teratogenicity [7].
Our patient had type 2 DM and a good 
metabolic compensation. He was hospital-
ized for sepsis associated with respiratory 
failure and admitted to the ICU, where the 
emerging episodic hypoglycemia was attrib-
uted to his septic state. But the hypoglycemia 
progressed, despite the fact that the inflam-
matory state remitted. A diagnostic work up 
investigated into the possible pathogenesis 
of the hypoglycemia and reasonably ruled 
out: an iatrogenic nature (metformin), or-
ganic endogenous causes (insulin, congeni-
Figure 1. Glucose and 
Valproic Acid level time 
course (on the abscissa 
the days from admission 
to the Neurology Unit)
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has a metabolic influence on insulin release 
at a pancreatic level [9]. Moreover, it has 
been hypothesized that VPA acts as a sub-
strate for the fatty acid β-oxidation pathway, 
leading to carnitine consumption. Therefore, 
when fatty acid β-oxidation is inhibited by a 
low carnitine level, the fasting hepatic glu-




glycemia, in particular VPA-induced, has 
not been commonly reported, nor is it in-
cluded in the side effects described in the 
VPA datasheet.
The case herein reported in an adult pa-
tient supports the hypothesis that VPA may 
induce hypoglycemia, by mechanisms and 
metabolic effects that remain to be defined, 
even at a therapeutical dosage.
Therefore, we strongly suggest that when-
ever there is a case of apparently unexplained 
hypoglycemia in a patient on chronic thera-
py with VPA, the possibility of there being 
an iatrogenic pathogenesis should be care-
fully evaluated.
As currently only anecdotal reports are 
available, the effect of VPA on glucose me-
tabolism should be better clarified by future 
investigations. Indeed, a better understand-
ing of these mechanisms may well lead 
to better and safer management of VPA 
therapy and may even prompt research on 
the possible, novel indications for metabolic 
control in patients with glucose intolerance.
Key points
 y VPA may induce hypoglycemia, even at a therapeutical dosage.
 y Cases of apparently unexplained hypoglycemia in patients on chronic VPA therapy should 
be carefully evaluated to rule out an iatrogenic pathogenesis.
 y Hopefully, future studies will shed light on the mechanisms underlying the hypoglycemia 
induced by VPA and the effect VPA has on the glucose metabolism.
fected the VPA half-life and the restoration 
of a normal glucose metabolism.
However, a VPA hepatotoxicity syndrome 
was ruled out by the normal liver function, 
including blood ammonia levels, and by the 
absence of jaundice.
The relationship between VPA and hy-
poglycemia has been reported above all in 
animal models.
Experiments in diabetic rats treated with 
VPA showed a dose-dependent reduction 
in blood glucose, which peaked around the 
21st day of administration (a reduction of 
52.79%), whilst in normal glycemic rats the 
peak was reached over the same period at 
a percentage of 15.63% [11]. These results 
and further findings on animal models [12] 
suggest that VPA has antidiabetic properties.
Moreover, literature has described some 
cases of neonatal hypoglycemia after in utero 
exposure to valproate [13-15].
Cases of VPA-induced hypoglycemia in 
adults have been reported almost exclusively 
in the context of hepatic failure due to VPA 
intoxication [16]. To the best of our knowl-
edge, there are very few reports on hypo-
glycemia induced by therapeutical levels of 
VPA [17]. VPA has not been included in the 
list of non-diabetic agents reported as being 
responsible for hypoglycemia [18].
Apart from hepatic failure, it may be hy-
pothesized that there are some other under-
lying mechanisms that mediate the hypogly-
cemic effect of VPA, i.e., insulin release, or its 
reduced clearance and/or interference with 
the glucose metabolism at multiple levels [9]. 
Indeed, on the basis that VPA may induce 
pancreatitis, it may be supposed that VPA 
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